Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12576421 | 0.91 | LMNA (0.53) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2895618 | 0.87 | NPSR1 (0.65) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2896990 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2892458 | 0.85 | ALDH1A1 (0.59) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2895361 | 0.85 | LMNA (0.61) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL3455905 | 0.84 | ALDH1A1 (0.67) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2891491 | 0.84 | AVPR1A (0.65) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL4532655 | 0.83 | AVPR1A (0.66) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2897064 | 0.83 | AVPR1A (0.61) | LMNANPSR1ALDH1A1MEN1HTT | |
| SCHEMBL2897856 | 0.83 | LMNA (0.59) | LMNANPSR1ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | claimed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | claimed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | claimed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | claimed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | claimed |
| EP-1618090-A1 | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-01-25 | — | — | EP | claimed |
| WO-2004089896-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2009073460-A2 | INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION | BAUSCH & LOMB INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD17B1 | LMNA 2486/4885NPSR1 1893/4885ALDH1A1 59/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | LMNA 4087/4885NPSR1 1147/4885ALDH1A1 58/4885 |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | HSD11B1, HSD3B1, HSD17B1 | LMNA 2486/4885NPSR1 1893/4885ALDH1A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.